Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors

Recent studies have demonstrated anxiolytic potential of pharmacological endocannabinoid (eCB) augmentation approaches in a variety of preclinical models. Pharmacological inhibition of endocannabinoid-degrading enzymes, such as fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), el...

Descripción completa

Detalles Bibliográficos
Autores principales: Bedse, Gaurav, Bluett, Rebecca J., Patrick, Toni A., Romness, Nicole K., Gaulden, Andrew D., Kingsley, Philip J., Plath, Niels, Marnett, Lawrence J., Patel, Sachin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917016/
https://www.ncbi.nlm.nih.gov/pubmed/29695817
http://dx.doi.org/10.1038/s41398-018-0141-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917016/
https://www.ncbi.nlm.nih.gov/pubmed/29695817
http://dx.doi.org/10.1038/s41398-018-0141-7

Ejemplares similares